INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

17d ago, source: Hosted on MSN

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript March 28, 2024 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58. INMB isn't one of the ...

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

10d ago, source:

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast ...

INMB INmune Bio, Inc.

13d ago, source: Seeking Alpha

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and ...

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

1mon ago, source: Business Insider

Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and ...

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

28d ago, source: ADVFN

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease ...

INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript

20d ago, source: Seeking Alpha

Ladies and gentlemen, greetings and welcome to the INmune Bio Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will ...

INmune Bio Inc INMB

6d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

17d ago, source: Insider Monkey

INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58. INMB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter ...

INmune Bio Inc INMB

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

17d ago, source: Insider Monkey

RJ Tesi: Yeah. So thank you. So INmune Bio is making progress on two fronts and we’re pretty proud of that. I will say the drug development landscape for the treatment in cognitive decline in ...